Matthew Lang, J.D.

Matthew Lang, J.D.

Chief Business OfficeratLyell Immunopharma· In proxies 2021–2024

Pay in FY2024-53% from the year before · Lyell Immunopharma stock -67.0% the same year

Matthew Lang, J.D. was paid $1.9M in FY2024 (Dec), down 53%. Lyell Immunopharma stock fell 67.0% that year.

Pay$100 in the stock at the end of FY21 → $8
Pay is from the Summary Compensation Table of each Lyell Immunopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lyell ImmunopharmaPublic company · 5 yr
    • Chief Business Officer2021 – Present · 5 yrStock in role -97%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?